OXIS : Biotech Companies Like Oxis International, Ready to Breakout Big
Miami, FL — (ReleaseWire) — 01/14/2015 — Investing in marijuana stocks as been referred to in the past as the “green rush”, especially after Colorado and Washington became the first states to legalize recreational cannabis. Businesses with no experience in the cannabis circuit were trying to move in to make some green of their own. Savvy penny stock investors soon realized the importance of being smart with their money and not investing in every “grow op” looking for funding.
The shift in cannabis culture can be a lucrative one, if the company can find a state with legal medical or recreational cannabis to operate in. The “cannabis for cash” concept is still a fairly new one, but has already seen some big changes. For example, take a company whose entire business model is growing medical grade cannabis for dispensaries. If the state, let’s take Florida for example, does not end up passing a medical or recreational cannabis initiative, that business is left with no options for success.
Biotech companies, like the up and coming Oxis International, Inc., derive the useful components from the cannabis plant, combine it with existing methods and then include it in a drug therapy or medicine, completely unassociated with the general legalization of cannabis.
Oxis International, Inc., has made some huge steps towards becoming a top player in the penny stock and the biotech game lately. Oxis recently named Anthony Cataldo as the Chief Executive Officer and President of of Oxis Biotech, Inc. a wholly owned subsidiary of Oxis International. Inc. Cataldo has a track record for building successful biotechs. From February 2011 to June 2013 Cataldo served as Chairman/CEO of Genesis Biopharma, inc. (Previous: GNBP), now known as Lion Biotechnologies, Inc., (LBIO) and currently trades over $8/share. Oxis has already benefited from his expertise as from early December up until recent, the stock price for Oxis Biotech has consistently remained in an uptrend moving as high as $0.0399 during the first few days of the new year.
Most notably, Oxis recently announced that it executed definitive agreements licensing certain assets for the treatment of Multiple Myeloma and initiated a consulting agreement with University of Pittsburgh’s Professor, Dr. Xiang-Qun(Sean)Xie (one of the world’s foremost cannabinoid research scientists). The American Cancer Society’s estimates for multiple myeloma in the United States for 2015 are about 26,850 new cases of multiple myeloma and about 11,240 deaths from multiple myeloma alone.
The license agreement provides Oxis Biotech, Inc an exclusive worldwide license to develop and commercialize therapies for the treatment of Multiple Myeloma (a type of cancer that attacks plasma cells in bone marrow). Dr. Xie joins Oxis Biotech as a consultant and member of the Science Advisory Board to further develop the assets licensed to Oxis Biotech, Inc. Among the mile-long track record of amazing accomplishments that Dr. Xie holds (See below), he is a recipient of the 2014 American Association of Pharmaceutical Scientists (AAPS) Outstanding Research Achievement Award.
Mr. Cataldo stated, “I wanted to leverage Dr. Xie’s significant experience and technologies, much the same way I did when I acquired highly valued patents from the NCI (NIH) for stage 4 Melanoma from the National Cancer Institute to form Lion Biotechnologies, Inc. (LBIO)”. In addition to this, University of Pittsburgh’s new Chancellor Patrick Gallagher encourages industry partnership of the University with OXIS.
About Oxis International
While there are other biotech companies working with cannabis, Oxis International has focused in with their definitive licensing agreement for treatment of Multiple Myeloma. The future for OXIS investors is looking to be a bright one, especially with a CEO like Cataldo taking the reigns and Dr. Xie leading the development of the infrastructure needed to deploy this therapy. Other biotech companies like GWPH and INSY have already built up their corner, and OXIS has put a strong leadership and research team in place which could put the company in a position to become a market leader in the cannabis biotech industry.For more information on this press release visit: http://www.releasewire.com/press-releases/release-574580.htm
Media Relations Contact
Adam Heimann
Email: Click to Email Adam Heimann
Web: http://egmfirm.com
© Acquiremedia 2015
View original:
OXIS : Biotech Companies Like Oxis International, Ready to Breakout Big
See which stocks are being affected by Social Media
